# Apreo Health

> Apreo Health is a clinical-stage medical device company in Menlo Park, California developing the BREATHE Airway Scaffold, a bronchoscopically delivered, self-expanding nitinol implant that relieves lung hyperinflation in patients with severe emphysema. Unlike existing valve and surgical treatments that collapse or remove lung tissue, the scaffold gently tents open damaged airways to release trapped air while sparing healthy tissue, aiming to expand who can be treated. The company raised a $130M Series B in August 2025 to run its pivotal BREATHE-3 trial and prepare for early commercialization.

- **Headquarters:** Menlo Park, California, United States
- **Founders:** Karun D. Naga (Co-founder & Chief Executive Officer), Marty Mayse, MD (Co-founder & Chief Scientific Officer)
- **Team size:** ~29 employees
- **Products:** Apreo BREATHE Airway Scaffold
- **Notable:** Closed an oversubscribed $130 million Series B in August 2025, co-led by Bain Capital Life Sciences and Norwest., Granted FDA Breakthrough Device Designation in May 2024., Presented first-in-human BREATHE 1&2 data in a late-breaking abstract at ATS 2025.

## Products & services

- **Apreo BREATHE Airway Scaffold** — An investigational, self-expanding nitinol scaffold delivered bronchoscopically to tent open targeted airways, releasing trapped air and relieving lung hyperinflation in severe emphysema. Its low-profile, flexible design is intended to reduce foreign body reaction, preserve side branches, and enable bilateral lung treatment.

## Achievements

- Closed an oversubscribed $130 million Series B in August 2025, co-led by Bain Capital Life Sciences and Norwest.
- Granted FDA Breakthrough Device Designation in May 2024.
- Presented first-in-human BREATHE 1&2 data in a late-breaking abstract at ATS 2025.
- Published six-month BREATHE 1&2 results in the American Journal of Respiratory and Critical Care Medicine.
- Reported no post-procedure pneumothorax in early trials, a common and dangerous complication of existing therapies.
- Treated the first patient in its pivotal BREATHE-3 trial in August 2025.

## Latest updates

- **2025-08** — Announced first patient treated in the pivotal BREATHE-3 trial of the BREATHE Airway Scaffold.
- **2025-08** — Closed $130M Series B financing to fund the pivotal trial and early commercialization.
- **2025-05** — Presented first-in-human BREATHE 1&2 data at ATS 2025 and published six-month results in AJRCCM.

## Links

- Website: https://apreohealth.com
- LinkedIn: https://www.linkedin.com/company/apreo-health

---

Profile page: https://yespress.io/apreo-health
Published by YesPress — https://yespress.io
Last updated: 2026-07-13